Dr
Jeffrey Rubasingham
MSt MRCS MRCP FRCR
Doctoral Student in Biomedical Engineering
Clinical Research Fellow
Email:
College: St Cross College
Location: Oxford
Site: Churchill Hospital
Research Building: Botnar Research Centre

Dr. Jeffrey Rubasingham is a specialist registrar in Clinical Oncology and the lead clinical research fellow for CEeDD, a National Institute of Health Research (NIHR) funded early-phase clinical trial investigating ultrasound-enhanced drug delivery for colorectal liver metastases. Concurrently, he is pursuing a DPhil in Biomedical Engineering (funded by Cancer Research UK) under the supervision of Professors Constantin Coussios, Robert Carlisle, and Rachel Kerr. His research focuses on the enhancement and monitoring of antibody therapy using ultrasound-mediated cavitation and passive acoustic mapping.

Dr. Rubasingham obtained his primary medical degree from the University of Birmingham and completed a master’s degree in Genomics at the University of Cambridge, where he researched histopathological associations of KRAS mutations in colorectal cancer, funded by Health Education England. He is a member of the Royal College of Surgeons, the Royal College of Physicians, and a fellow of the Royal College of Radiologists.

  1. Enhancement and monitoring of antibody therapy in cancer patients by ultrasound-mediated cavitation and passive acoustic mapping.
  2. Clinical translation of ultrasound-mediated immunomodulation in solid tumours using innovative trial design.

BUBBL

The Lancet breast cancer commission
Dodwell D,  Coles CE,  Earl H,  Anderson BO,  Barrios CH,  Bienz M,  Bliss JM,  Cameron DA,  Cardoso F,  Cui W,  Francis PA,  Jagsi R,  Knaul FM,  McIntosh SA,  Phillips K-A,  Radbruch L,  Thompson MK,  André F,  Abraham JE,  Bhattacharya IS,  Franzoi MA,  Drewett L,  Fulton A,  Kazmi F,  Inbah Rajah D,  Mutebi M,  Ng D,  Ng S,  Olopade OI,  Rosa WE,  Rubasingham J,  Spence D,  Stobart H,  Vargas Enciso V,  Vaz-Luis I,  et al. (2024)
Palliative radiotherapy: survival prognostic factors - single-centre retrospective cohort study.
Cooper S,  Denholm M,  Malek AS,  Rubasingham JA,  Tsang D,  et al. (2024)
Sonosensitive cavitation nuclei-a customisable platform technology for enhanced therapeutic delivery
Lyons B,  Balkaran JPR,  Dunn-Lawless D,  Lucian V,  Keller SB,  O'Reilly CS,  Hu L,  Rubasingham J,  Nair M,  Carlisle R,  Stride E,  Gray M,  Coussios C,  et al. (2023)
The Lancet Breast Cancer Commission: tackling a global health, gender, and equity challenge.
Coles CE,  Anderson BO,  Cameron D,  Cardoso F,  Horton R,  Knaul FM,  Mutebi M,  Lee N,  Lancet Breast Cancer Commission ,  et al. (2022)
Improving Waiting Times from Decision to Treat to Starting Treatment in Head and Neck Cancers: An Audit of the 17-day Pathway
Rubasingham J,  Gemmill J,  James E,  Twyman N,  Gatfield E,  Barnett G,  Benson R,  Jadon R,  et al. (2022)
The challenges of managing immunotherapy-induced type 1 diabetes mellitus presenting as diabetic ketoacidosis: a case report
Tharmakulasingam S,  Rubasingham J,  Mithra S,  Cooper S,  Malek A,  Dancey G,  Islam M,  et al. (2020)
Pulmonary sarcoidosis masquerading as metastatic cervical cancer: a pitfall in CT scans and positron emission tomography (PET).
Rubasingham J,  Marzouk S,  Madhavan K,  Sioftanos G,  Liyanage SH,  et al. (2020)
Developing a nurse consultant-led immunotherapy services in a district general hospital
Muthukumar D,  Sheen L,  Rubasingham J,  Saunders E,  et al. (2019)
A case of hyperprogression of lung cancer following atezolizumab
Muthukumar D,  Saunders E,  Rubasingham J,  Nagarajah V,  et al. (2019)